Modern Experience in Pharmacotherapy of Irritable Bowel Syndrome in Children

This review examines modern approaches to the diagnosis and treatment of irritable bowel syndrome (IBS) in children, one of the most common functional disorders of the gastrointestinal tract. IBS is characterized by chronic abdominal pain, intestinal motility disorders and stool changes, which significantly reduces the quality of life of patients. The article analyzes in detail the pathogenetic mechanisms of IBS, including the role of the gut–brain axis, gut microbiota and neuroendocrine factors. Special attention is paid to the pharmacotherapy of IBS in children, including the use of antidepressants, probiotics and herbal components, as well as the role of correctors of the motor activity of the digestive tract in relieving symptoms. Modern recommendations on the use of various classes of antidepressants are considered, taking into account their pharmacokinetic and pharmacodynamic characteristics. The prospects of using probiotics and herbal preparations in the complex therapy of IBS are also analyzed. The data obtained confirm the need for a personalized approach to the treatment of IBS, taking into account the genetic and physiological characteristics of patients.

1. Alyasi AS, Altawili MA, Alabbadi AF, et al. Pharmacological Management for Pediatric Irritable Bowel Syndrome: A Review. Cureus. 2023;15(11):e49197. https://doi.org/10.7759/cureus.49197

2. Halland M, Saito YA. Irritable bowel syndrome: new and emerging treatments. BMJ. 2015;350:h1622. https://doi.org/10.1136/bmj.h1622

3. Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017;6(11):99. https://doi.org/10.3390/jcm6110099

4. Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology. 2016:S00165085(16)00181-5. https://doi.org/10.1053/j.gastro.2016.02.015

5. Soares RL. Irritable bowel syndrome: a clinical review. World J Gastroenterol. 2014;20(34):12144–12160. https://doi.org/10.3748/wjg.v20.i34.12144

6. Yu SJ, Lee HS, Gung HJ, et al. IBS Research Study Group of the Korean Society of Neurogastroenterology and Motility. Efficacy of a Restrictive Diet in Irritable Bowel Syndrome: A Systematic Review and Network Meta-analysis. Korean J Gastroenterol. 2022;80(1):6– 16. https://doi.org/10.4166/kjg.2022.014

7. Ng QX, Soh AYS, Loke W, et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345–349. https://doi.org/10.2147/JIR.S174982

8. Rowland I, Gibson G, Heinken A, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1–24. https://doi.org/10.1007/s00394-0171445-8

9. Gill PA, Inniss S, Kumagai T, et al. The Role of Diet and Gut Microbiota in Regulating Gastrointestinal and Inflammatory Disease. Front Immunol. 2022;13:866059. https://doi.org/10.3389/fimmu.2022.866059

10. Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One. 2015;10(5):e0126982. https://doi.org/10.1371/journal.pone.0126982

11. Rughwani T. Current Awareness and Tools Available for StressInduced IBS in Children. 2024. In: Digital Commons @ Garrisburg University: Website. Available online: https://digitalcommons.harrisburgu.edu/dandt/13. Accessed on August 31, 2024.

12. Chogle A, Mintjens S, Saps M. Pediatric IBS: an overview on pathophysiology, diagnosis and treatment. Pediatr Ann. 2014;43(4):e76–e82. https://doi.org/10.3928/0090448120140325-08

13. Algera J, Lövdahl J, Sjölund J, et al. Managing pain in irritable bowel syndrome: current perspectives and best practice. Expert Rev Gastroenterol Hepatol. 2023;17(9):871–881. https://doi.org/10.1080/17474124.2023.2242775

14. Jing F, Zhang J. Metabolic kinetics of 5-hydroxytryptamine and the research targets of functional gastrointestinal disorders. Dig Dis Sci. 2014;59(11):2642–2648. https://doi.org/10.1007/s10620-014-3244-x

15. Chen M, Ruan G, Chen L, et al. Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome. Front Endocrinol (Lausanne). 2022;13:817100. https://doi.org/10.3389/fendo.2022.817100

16. Fu R, Chen M, Chen Y, et al. Expression and clinical significance of 5-HT and 5-HT3R in the intestinal mucosa of patient with diarrhea-type irritable bowel syndrome. Exp Ther Med. 2019;17(4):3077–3082. https://doi.org/10.3892/etm.2019.7297

17. Stasi C, Bellini M, Gambaccini D, et al. Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study. J Neurogastroenterol Motil. 2017;23(3):428–434. https://doi.org/10.5056/jnm16155

18. Kridler J, Kamat D. Irritable Bowel Syndrome: A Review for General Pediatricians. Pediatr Ann. 2016;45(1):e30–e33. https://doi.org/10.3928/00904481-20151208-01

19. Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145(6):1262–1270.e1. https://doi.org/10.1053/j.gastro.2013.08.048

20. Palsson OS, Whitehead WE, van Tilburg MA, et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016:S0016-5085(16)00180-3. https://doi.org/10.1053/j.gastro.2016.02.014

21. Singh SV, Ganguly R, Jaiswal K, et al. Molecular signalling during cross talk between gut brain axis regulation and progression of irritable bowel syndrome: A comprehensive review. World J Clin Cases. 2023;11(19):4458–4476. https://doi.org/10.12998/wjcc.v11.i19.4458

22. Appleton J. The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. Integr Med (Encinitas). 2018;17(4):28–32.

23. Mayer EA, Ryu HJ, Bhatt RR. The neurobiology of irritable bowel syndrome. Mol Psychiatry. 2023;28(4):1451–1465. https://doi.org/10.1038/s41380-023-01972-w

24. Cerdó T, García-Santos JA, Rodríguez-Pöhnlein A, et al. Impact of Total Parenteral Nutrition on Gut Microbiota in Pediatric Population Suffering Intestinal Disorders. Nutrients. 2022;14(21):4691. https://doi.org/10.3390/nu14214691

25. Craven LJ, Silverman M, Burton JP. Transfer of altered behaviour and irritable bowel syndrome with diarrhea (IBS-D) through fecal microbiota transplant in mouse model indicates need for stricter donor screening criteria. Ann Transl Med. 2017;5(24):490. https://doi.org/10.21037/atm.2017.10.03

26. De Palma G, Lynch MD, Lu J, et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9(379):eaaf6397. https://doi.org/10.1126/scitranslmed.aaf6397

27. Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol. 2018;24(21):2211–2235. https://doi.org/10.3748/wjg.v24.i21.2211

28. Donnet AS, Hasan SS, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: patient expectations and perceptions. Therap Adv Gastroenterol. 2022;15:17562848221074208. https://doi.org/10.1177/17562848221074208

29. Rexwinkel R, de Bruijn CMA, Gordon M, et al. Pharmacologic Treatment in Functional Abdominal Pain Disorders in Children: A Systematic Review. Pediatrics. 2021;147(6):e2020042101. https://doi.org/10.1542/peds.2020-042101

30. Dwyer JB, Bloch MH. Antidepressants for Pediatric Patients. Curr Psychiatr. 2019;18(9):26–42F.

31. Bonilla S, Nurko S. Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives. Clin Exp Gastroenterol. 2018;11:365–372. https://doi.org/10.2147/CEG.S146646

32. Deodhar M, Rihani SBA, Darakjian L, et al. Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition. Pharmaceutics. 2021;13(2):148. https://doi.org/10.3390/pharmaceutics13020148

33. Huang X, Li C, Li C, et al. CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population. Front Pharmacol. 2021;12:730461. https://doi.org/10.3389/fphar.2021.730461

34. Maciaszek J, Pawłowski T, Hadryś T, et al. The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression. Int J Mol Sci. 2023;24(17):13459. https://doi.org/10.3390/ijms241713459

35. Ford AC, Wright-Hughes A, Alderson SL, et al. ATLANTIS trialists. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773–1785. https://doi.org/10.1016/S0140-6736(23)01523-4

36. Nassan M, Nicholson WT, Elliott MA, et al. Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Mayo Clin Proc. 2016;91(7):897–907. https://doi.org/10.1016/j.mayocp.2016.02.023

37. Dean L. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. In: Medical Genetics Summaries. Pratt VM, Scott SA, Pirmohamed M, et al., eds. Bethesda (MD): National Center for Biotechnology Information (US); 2017.

38. Radosavljevic M, Svob Strac D, Jancic J, Samardzic J. The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy. Genes (Basel). 2023;14(5):1095. https://doi.org/10.3390/genes14051095

39. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24(6):350–362. https://doi.org/10.1038/s41576-022-00572-8

40. Thümmler S, Dor E, David R, et al. Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6. Front Psychiatry. 2018;9:2. https://doi.org/10.3389/fpsyt.2018.00002

41. Austin-Zimmerman I, Wronska M, Wang B, et al. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. Genes (Basel). 2021;12(11):1758. https://doi.org/10.3390/genes12111758

42. Lam D, Ancelin ML, Ritchie K, et al. Genotype-dependent associations between serotonin transporter gene (SLC6A4) DNA methylation and late-life depression. BMC Psychiatry. 2018;18(1):282. https://doi.org/10.1186/s12888-018-1850-4

43. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010;68(6):536–543. https://doi.org/10.1016/j.biopsych.2010.04.034

44. Jukic M, Milosavljević F, Molden E, Ingelman-Sundberg M. Pharmacogenomics in treatment of depression and psychosis: an update. Trends Pharmacol Sci. 2022;43(12):1055–1069. https://doi.org/10.1016/j.tips.2022.09.011

45. Aka I, Bernal CJ, Carroll R, et al. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J Pers Med. 2017;7(4):14. https://doi.org/10.3390/jpm7040014

46. Lu PL, Velasco-Benítez CA, Saps M. Sex, Age, and Prevalence of Pediatric Irritable Bowel Syndrome and Constipation in Colombia: A Population-based Study. J Pediatr Gastroenterol Nutr. 2017;64(6):e137–e141. https://doi.org/10.1097/MPG.0000000000001391

47. Karunanayake A, Devanarayana NM, Rajindrajith S. Early life events in functional abdominal pain disorders in children. PLoS One. 2022;17(11):e0275419. https://doi.org/10.1371/journal. pone.0275419

48. Koppen IJ, Nurko S, Saps M, et al. The pediatric Rome IV criteria: what’s new? Expert Rev Gastroenterol Hepatol. 2017;11(3):193–201. https://doi.org/10.1080/17474124.2017.1282820

49. Trinkley KE, Nahata MC. Medication management of irritable bowel syndrome. Digestion. 2014;89(4):253–267. https://doi.org/10.1159/000362405

50. Roohafza H, Pourmoghaddas Z, Saneian H, Gholamrezaei A. Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Neurogastroenterol Motil. 2014;26(11):1642–1650. https://doi.org/10.1111/nmo.12444

51. Seetharaman J, Poddar U, Yachha SK, et al. Efficacy of amitriptyline in pediatric functional abdominal pain disorders: A randomized placebo-controlled trial. J Gastroenterol Hepatol. 2022;37(4):685–691. https://doi.org/10.1111/jgh.15765

52. Saps M, Youssef N, Miranda A, et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology. 2009;137(4):1261–1269. https://doi.org/10.1053/j.gastro.2009.06.060

53. Crawford J, Tran P, Shaw JS, Shaw RJ. Current Pharmacological Treatments for Childhood-Onset Somatic Symptom and Related Disorders (SSRD) and Functional Gastrointestinal Disorders (FGID). Current Treatment Options in Psychiatry. 2020;7:120–143. https://doi.org/10.1007/s40501-020-00209-9

54. Guandalini S, Magazzù G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51(1):24–30. https://doi.org/10.1097/MPG.0b013e3181ca4d95

55. Sudha MR, Jayanthi N, Aasin M, et al. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microbes. 2018;9(4):563–572. https://doi.org/10.3920/BM2017.0129

56. Francavilla R, Miniello V, Magistà AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126(6):e1445–e1452. https://doi.org/10.1542/peds.2010-0467

57. Menon J, Thapa BR, Kumari R, et al. Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial. J Pediatr Gastroenterol Nutr. 2023;76(1):14–19. https://doi.org/10.1097/MPG.0000000000003622

58. Shulman RJ, Hollister EB, Cain K, et al. Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol. 2017;15(5):712–719.e4. https://doi.org/10.1016/j.cgh.2016.03.045

59. Ogawa N, Nakajima S, Tamada K, et al. Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages. Arch Biochem Biophys. 2021;711:109029. https://doi.org/10.1016/j.abb.2021.109029

60. Karabulut GS, Beşer OF, Erginöz E, et al. The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment. J Neurogastroenterol Motil. 2013;19(1):90–93. https://doi.org/10.5056/jnm.2013.19.1.90

61. Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. J Pharmacobiodyn. 1990;13(7):448–453. https://doi.org/10.1248/bpb1978.13.448